{"title":"<i>Erratum to:</i> \"Experiences and Acceptability of Serial Lymph Node and Gut Biopsies Among Young Women Enrolled in an HIV Cure-Related Trial in Durban, South Africa\".","authors":"","doi":"10.1177/08892229261499853","DOIUrl":"10.1177/08892229261499853","url":null,"abstract":"","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"385"},"PeriodicalIF":1.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nermin Akcali, Cüneyd Yavas, Sajjad Eslamkhah, Sonat Sina Canturk, Kevser Eryildiz, Nisa Aslan, Zeynep Nur Ozcan, Lutfiye Karcioglu Batur
{"title":"The Effect of rs7975232 (ApaI) and rs731236 (TaqI) <i>VDR</i> Polymorphisms on HIV/AIDS Prevalence and Mortality: An International Population Genetics Analysis.","authors":"Nermin Akcali, Cüneyd Yavas, Sajjad Eslamkhah, Sonat Sina Canturk, Kevser Eryildiz, Nisa Aslan, Zeynep Nur Ozcan, Lutfiye Karcioglu Batur","doi":"10.1177/08892229261487810","DOIUrl":"10.1177/08892229261487810","url":null,"abstract":"<p><p>In this study, the relationship between the allele and genotype frequencies of the rs7975232 (ApaI) and rs731236 (TaqI) polymorphisms of the vitamin D receptor (<i>VDR</i>) gene and country-based HIV/AIDS prevalence and mortality rates were examined using Spearman rank correlation analyses. These Spearman analyses were validated for significance using the False Discovery Rate (FDR) method, considering traditional criteria (Adjusted <i>p</i>-value <.05). The findings revealed that ApaI_CC and TaqI_TT genotype frequencies showed weak inverse correlations with HIV/AIDS prevalence and mortality rates (ρ ≈ -0.30 and -0.25); however, these correlations were not statistically significant after FDR correction (<i>p</i>_adj > 0.05). These results suggest that <i>VDR</i> polymorphisms showed no statistically significant association with HIV/AIDS epidemiology in this ecological analysis; at most, these findings generate a population-level hypothesis that vitamin D-mediated immune responses may warrant further study. These findings should be regarded as exploratory and hypothesis-generating, and may inform future individual-level genotype-phenotype and functional studies.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"350-358"},"PeriodicalIF":1.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149011831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mzwakhe Wiseman Ngcobo, Ntombifuthi Langa, Ayanda Zulu, Whitney Tran, Vanessa Pillay, Maud Mthembu, Lihle Ngcongo, Ali Ahmed, Deborah Mindry, Nithin Lutchminarain, Zaza Ndhlovu, Megha L Mehrotra, Devi Sengupta, Elena Vendrame, Thumbi Ndung'u, Karine Dubé, Krista L Dong
{"title":"Experiences and Acceptability of Serial Lymph Node and Gut Biopsies Among Young Women Enrolled in an HIV Cure-Related Trial in Durban, South Africa.","authors":"Mzwakhe Wiseman Ngcobo, Ntombifuthi Langa, Ayanda Zulu, Whitney Tran, Vanessa Pillay, Maud Mthembu, Lihle Ngcongo, Ali Ahmed, Deborah Mindry, Nithin Lutchminarain, Zaza Ndhlovu, Megha L Mehrotra, Devi Sengupta, Elena Vendrame, Thumbi Ndung'u, Karine Dubé, Krista L Dong","doi":"10.1177/08892229261491477","DOIUrl":"10.1177/08892229261491477","url":null,"abstract":"<p><p>Human immunodeficiency virus (HIV) persists in diverse body tissues, including the gut, lymph nodes (LNs), and lungs, requiring direct sampling to characterize heterogeneous reservoirs. HIV cure-related trials may include tissue sampling to evaluate intervention efficacy and mechanisms to eliminate viral reservoirs. Repeated invasive sampling carries risks that must be balanced against safety, acceptability, and scientific value. We assessed the experiences of young women undergoing serial excisional LN and gut biopsies during an HIV cure-related trial in South Africa. We conducted a qualitative secondary analysis of in-depth interviews (IDIs) with women enrolled in a Phase 2A HIV cure-related trial (NCT05281510) that included an analytical treatment interruption (ATI). We conducted IDIs at enrollment and pre-ATI at the Females Rising through Education, Support and Health research site in Durban, South Africa, in <i>isiZulu</i>. We audio-recorded, transcribed, translated, and deidentified the interviews and analyzed them using inductive conventional content analysis. We interviewed 19 participants. Each underwent LN excision 1-3 times (mean 2.6) and gut biopsy 0-3 times (mean 2.5). Motivations included scientific curiosity and contributing to future generations. LN excision was generally painless, although some reported itching and slow healing. Gut biopsies caused abdominal pressure and transient bloating. One adverse event occurred among 48 LN excisions. Initial apprehension was common, but clear communication, supportive staff, and recognition of contributions fostered trust and willingness to undergo repeat procedures. Serial tissue sampling was acceptable among young South African women despite some discomfort. Altruism was a primary motivator, while clear communication and participant-centered care were critical to supporting informed participation and repeat sampling.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"359-368"},"PeriodicalIF":1.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13659307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Revisiting What HIV in the Brain Can Teach Us About SARS-CoV-2 Neurological Complications.","authors":"Layan Taher, Jekzaly Arellano, Lena Al-Harthi","doi":"10.1177/08892229261491499","DOIUrl":"10.1177/08892229261491499","url":null,"abstract":"<p><p>In 2021, a Perspective article suggested that principles of HIV neuropathogenesis could provide a conceptual framework for understanding the neurological complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection when mechanistic evidence was limited. Five years later, extensive clinical, neuropathological, and experimental studies allow reassessment of that framework. Current evidence has shifted emphasis away from direct viral infection of the central nervous system toward host-mediated mechanisms involving persistent immune activation, endothelial dysfunction, glial activation, thromboinflammation, and disruption of the neuroimmune axis. At the same time, persistent viral antigens and adaptive immune responses, including autoantibodies in subsets of patients, have expanded our understanding of the biological heterogeneity underlying post-acute sequelae of SARS-CoV-2 infection with neurological manifestations. This Perspective revisits the original framework in light of these advances and examines how concepts derived from HIV neuropathogenesis continue to inform our understanding of persistent neurological dysfunction following SARS-CoV-2 infection.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"335-342"},"PeriodicalIF":1.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13718530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karsten Eichholz, Afam A Okoye, Benjamin D Varco-Merth, Jiaxin Gong, John Bui, Joe Hou, Hans-Peter Kiem, Daniel Hayball, Mark Hoenerhoff, Samuel T Robinson, Christopher W Peterson, Lawrence Corey, Daniel Corey
{"title":"Safety of Autologous Infusion of CER T Cells in Nonhuman Primates.","authors":"Karsten Eichholz, Afam A Okoye, Benjamin D Varco-Merth, Jiaxin Gong, John Bui, Joe Hou, Hans-Peter Kiem, Daniel Hayball, Mark Hoenerhoff, Samuel T Robinson, Christopher W Peterson, Lawrence Corey, Daniel Corey","doi":"10.1177/08892229261490969","DOIUrl":"10.1177/08892229261490969","url":null,"abstract":"<p><p>Cellular immunotherapies have shown great promise in the treatment of various diseases. Chimeric engulfment receptor (CER)-engineered T cells were developed to utilize the extracellular T-cell immunoglobulin and mucin domain-containing 4 (TIM-4) domain and intracellular engulfment signaling domains to target and enhance phagocytosis and T-cell cytotoxic function. These processes are activated through TIM-4 binding with phosphatidylserine (PS), a pro-phagocytic \"eat me\" signal. HIV infection has been shown to induce extracellular PS exposure shortly after infection, and engineered CER T cells have been shown to kill CD4<sup>+</sup> T cells infected with simian immunodeficiency virus (SIV) <i>in vitro</i>. In this study, we infused two rhesus macaques (RMs) with CER-1236 T cells (the iteration of CER T cells currently moving forward in human clinical trials for cancer) and evaluated safety, the tissue distribution of the CER-1236 T cells, and antiviral activity against SIV (SIVmac239). Prior to infusions, RMs underwent SIV infection, antiretroviral therapy (ART), and ART cessation. The infusions were well tolerated. Neither of the macaques exhibited clinical evidence of illness nor changes in vital signs, serum chemistry, hematology, or other evaluated physiological parameters beyond what is typically observed with SIV infection. Post-infusion proliferation of CER T cells in PBMC was limited and seen with cells manufactured by the Prodigy system. Histologic and flow cytometry evaluation from post-infusion tissue biopsies and necropsy revealed tissue detection of CER T cells in bronchoalveolar lavage fluid with intermittent detection of infused cells in lymphoid tissue in concert with the limited expansion of T cells in PBMC. No laboratory or clinical evidence of hepatic, splenic, bone marrow, or CNS alterations was noted, and no evidence of <i>in vivo</i> suppression of SIVmac239 was observed as a result of the infusions. The CER-1236 T cell infusions were not associated with any discernable histopathological toxicity. This safety profile of CER-1236 T cells in nonhuman primates portends well for its potential for clinical development, especially for tumors with high expression of the tissue damage receptor PS. Optimization of <i>in vivo</i> functionality will be required for CER T cells to be effective against HIV infection.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"369-378"},"PeriodicalIF":1.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Haoxi Shi, Juan Meng, Yimin Cao, Yiteng Zhao, Ying Xing, Jian Du, Shangyu Li, Ziting Liu, Yuping Chen, Feng Zhao
{"title":"Identification of Two Novel HIV-1 Unique Recombinant Forms Involving CRF07_BC and CRF08_BC Among ART-Failing Patients in Hebei, China.","authors":"Haoxi Shi, Juan Meng, Yimin Cao, Yiteng Zhao, Ying Xing, Jian Du, Shangyu Li, Ziting Liu, Yuping Chen, Feng Zhao","doi":"10.1177/08892229261490627","DOIUrl":"10.1177/08892229261490627","url":null,"abstract":"<p><p>The continuous HIV-1 recombination forms circulating in China poses a persistent challenge to epidemic control. And this study identifies two novel unique recombinant forms (URFs), BDNY017 and BDK025, from antiretroviral therapy (ART)-failing patients in Hebei Province. Near full-length genomic analysis revealed that BDNY017 is a triple mosaic of CRF08_BC, CRF07_BC, and subtype B, whereas BDK025 is a dual recombinant of CRF07_BC and CRF08_BC. Genotypic resistance testing further uncovered M184V, A98G, and E138K mutations in BDNY017, while BDK025 carried no major <i>pol-region</i> resistance mutations. Notably, the report of CRF08_BC-involved URFs in northern China, expanding the known geographic distribution of such recombinants beyond their traditional southwestern focus and underscoring the urgent need for enhanced molecular surveillance, particularly among ART-failing individuals, to track emerging recombinants and assess their potential impact on treatment outcomes and transmission dynamics.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"379-384"},"PeriodicalIF":1.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xenia Choc-Cano, Maricarmen Pelayo-Madrigal, Eduardo Gutiérrez-Maya, Ivan Zepeda-Quiroz, Sebastián Toledo-Ramírez, Barrera-Mota Brenda, Jimenez-Baez Valeria, Ciria Vázquez-Macias, Daniel Juárez-Villa
{"title":"Clinical Factors Associated with Short-Term Decline in Estimated Glomerular Filtration Rate in People Living with HIV Receiving Antiretroviral Therapy: A Prospective Cohort Study.","authors":"Xenia Choc-Cano, Maricarmen Pelayo-Madrigal, Eduardo Gutiérrez-Maya, Ivan Zepeda-Quiroz, Sebastián Toledo-Ramírez, Barrera-Mota Brenda, Jimenez-Baez Valeria, Ciria Vázquez-Macias, Daniel Juárez-Villa","doi":"10.1177/08892229261487815","DOIUrl":"10.1177/08892229261487815","url":null,"abstract":"<p><p>HIV infection remains a significant public health challenge. Although antiretroviral therapy has substantially improved survival, chronic complications such as renal impairment increase morbidity and mortality, making the estimated glomerular filtration rate (eGFR) crucial for early detection. This prospective, observational, and analytical cohort study aimed to identify the clinical, sociodemographic, and laboratory factors associated with short-term eGFR decline in people living with HIV (PLWH) over a 6-month follow-up at a second-level Mexican hospital. We included 166 PLWH aged > 18 years, collecting data on serum creatinine, eGFR, viral load, and CD4<sup>+</sup> T cell counts. Patients were stratified based on the magnitude of eGFR decline into four groups (<5, 5-9, 10-19, and ≥20 mL/min/1.73 m<sup>2</sup>). The median age was 35 years (91% male). Median eGFR was 101.81 mL/min/1.73 m<sup>2</sup> at baseline and 100.54 mL/min/1.73 m<sup>2</sup> at 6 months. Most patients achieved virological suppression, and only 2.4% developed chronic kidney disease. Group analysis revealed a significant association between a greater short-term eGFR decline and advanced age, unemployment, and opportunistic infections. In conclusion, short-term renal decline was primarily associated with older age and unemployment. Although chronic kidney disease incidence was low, evaluating short-term eGFR decline allowed for the identification of clinically relevant alterations, highlighting the importance of periodic renal monitoring, particularly in clinically and socially vulnerable patients.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"343-349"},"PeriodicalIF":1.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Şeyma Yavuz, Altan Aksoy, Sengül Üçer, Sami Kınıklı
{"title":"Evaluation of Tetanus Immunity in People Living with HIV: Reassessment of the Booster Dose Schedule.","authors":"Şeyma Yavuz, Altan Aksoy, Sengül Üçer, Sami Kınıklı","doi":"10.1177/08892229261507443","DOIUrl":"https://doi.org/10.1177/08892229261507443","url":null,"abstract":"<p><p>The decrease in CD4<sup>+</sup> T lymphocyte count in people living with HIV causes a weakening of the immune response developed against the vaccine. This study aims to determine tetanus antibody levels in people living with HIV and to evaluate the relationship between these levels and various parameters. It aims to characterize those who lack protective antibody levels despite documented vaccination within the recommended 10-year interval and to question the adequacy of the current booster dose timing. Tetanus antibody levels were measured in serum samples from people living with HIV followed at the Infectious Diseases Clinic, using the <i>Clostridium tetani</i> toxin IgG (VIRCLIA; Vircell, Spain) kit by chemiluminescence immunoassay and interpreted according to the World Health Organization recommendations. All participants had a documented tetanus toxoid dose within the preceding 10 years, verified through the national Vaccination Tracking System. The study included 100 people living with HIV (88 men, 12 women; ages 20-73 years, mean = 38.04). Only age (<i>p</i> < .001) and time since last vaccination (<i>p</i> = .004) had a statistically significant effect on tetanus antibody levels. For protective levels (≥0.20 IU/mL), only age was significant (<i>p</i> = .008), with higher protective levels in the 20-39 age group than in those over 40. Despite vaccination within the preceding 10 years, 17% (<i>n</i> = 17) lacked protective antibody levels: 7.9% of those aged 20-39 versus 32.4% of those aged ≥40 (odds ratio = 5.57, 95% confidence interval: 1.77-17.48), and 25.0% of those vaccinated 5-10 years earlier versus 11.7% of those vaccinated within the previous 5 years. HIV-related clinical and immunological parameters were not significantly associated with tetanus antibody levels. Nevertheless, nearly one in five people living with HIV considered up-to-date lacked protective antibody levels, predominantly those aged ≥40 years. In this group, serological testing or a booster dose earlier than the recommended 10-year interval may be warranted.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"8892229261507443"},"PeriodicalIF":1.0,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Determinants of Virological Suppression Among HIV Patients on Antiretroviral Therapy at Debre Tabor Comprehensive Specialized Hospital: A Cross-Sectional Study.","authors":"Ayenew Assefa, Mulat Erkihun, Ayenew Berhan, Andargachew Almaw, Teklehaimanot Kiros, Birhanu Getie, Birhanemaskal Malkamu, Biruk Legese, Bekele Sharew, Taklo Simeneh Yazie, Mitikie Wondmagegn, Alemie Fentie, Temesgen Ayalew, Getu Abeje, Dessie Tegegne, Tazeb Molla","doi":"10.1177/08892229261504555","DOIUrl":"https://doi.org/10.1177/08892229261504555","url":null,"abstract":"<p><p>Antiretroviral therapy (ART) has played an important role in the decline of HIV/AIDS-related morbidity and mortality. However, the growing challenge of virological non-suppression compromises the effectiveness of current treatment options. Therefore, this study aimed to identify determinants of virological suppression among people living with HIV on ART at Debre Tabor Comprehensive Specialized Hospital, northwest Ethiopia. A facility-based cross-sectional study was conducted from February to May 2024. A structured questionnaire was utilized to gather sociodemographic data, while clinical data were obtained by examining the patients' medical records. Blood samples were collected to measure viral load. A binary logistic regression model was employed to determine the associated factors, with a <i>p</i> value < .05 at 95% confidence interval deemed statistically significant. The study included 258 participants who had ART follow-up for at least 6 months. The median age of the patients was 40, and the majority (36.8%) were in the 35-44 age range. About 95.7% of the patients achieved virological suppression, whereas 11 participants (4.3%) did not. ART adherence, CD4 count at study time, and age were significant predictors of virological suppression. Virological suppression was demonstrated in the majority (95.7%) of patients receiving ART, which aligns with the joint United Nations Program on HIV/AIDS viral suppression goal on ART program. Managing age-related factors and intensive adherence counseling should be prioritized to maintain and increase virological suppression rates.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"8892229261504555"},"PeriodicalIF":1.0,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ken Ho, Stacey Edick, Ashley Zyhowski, Amanda Swistok, Leslie Meyn, Lisa Rohan, Lin Wang, Nobuyuki Matoba, Amanda Lasnik, Joshua Fuqua, Hans Spiegel, Douglas Hartman, Randall E Brand, Ross D Cranston, Ian McGowan, Kenneth Palmer, Rhonda M Brand
{"title":"A Randomized, Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Douche Administered Rectally to HIV-1 Seronegative Adults (the PREVENT Study).","authors":"Ken Ho, Stacey Edick, Ashley Zyhowski, Amanda Swistok, Leslie Meyn, Lisa Rohan, Lin Wang, Nobuyuki Matoba, Amanda Lasnik, Joshua Fuqua, Hans Spiegel, Douglas Hartman, Randall E Brand, Ross D Cranston, Ian McGowan, Kenneth Palmer, Rhonda M Brand","doi":"10.1177/08892229261502024","DOIUrl":"https://doi.org/10.1177/08892229261502024","url":null,"abstract":"<p><p>The availability of oral and long-acting injectable pre-exposure prophylaxis (PrEP) has transformed human immunodeficiency virus (HIV) prevention; however, some individuals may prefer behaviorally congruent, nonsystemic, on-demand rectal PrEP options that avoid chronic systemic exposure. The Q-Griffithsin (Q-GRFT) rectal douche is a novel, user-controlled PrEP candidate, containing a natural (red alga-derived), potent broad-spectrum antiviral lectin for pericoital rectal use. This first-in-human Phase 1 trial evaluated the safety, pharmacokinetics (PKs), pharmacodynamics (PDs), and acceptability of a single Q-GRFT rectal douche dose. Sixteen HIV-negative participants (eight female and eight male) with a history of recent receptive anal intercourse were enrolled in this randomized, double-blind study. Following single-dose administration, blood, rectal fluid, and rectal tissue samples were collected for safety, PK, and PD analyses using an <i>ex vivo</i> rectal explant HIV challenge model. Acceptability was measured using structured questionnaires. The Q-GRFT douche was safe with no Grade 3 or 4 adverse events or significant histological abnormalities. Acceptability was high at 93% of the study product. At 1 h postdose, geometric mean (range) Q-GRFT concentrations were 522.18 ng/mL (52.8-12,482.2) in rectal swab eluate and 6.85 µg (0.80-51.07) in rectal tissue, declining over 24 h. Q-GRFT was not detectable in plasma. Higher individual tissue drug levels correlated with reduced HIV infectivity in both rectal eluate (<i>p</i> = 0.036) and tissue explant (<i>p</i> = 0.003). In this first-in-human study, a single administration of Q-GRFT as a rectal douche demonstrated favorable safety, acceptability, and high local drug exposure without systemic absorption, supporting further evaluation as an on-demand, nonsystemic rectal PrEP strategy.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"8892229261502024"},"PeriodicalIF":1.0,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}